查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011055

非處方藥市場：2026-2032 年全球市場以藥物類型、劑型、通路、年齡層和最終用戶預測。

Over The Counter Drugs Market by Drug Type, Product Form, Distribution Channel, Age Group, End-user - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，非處方藥 (OTC) 市場價值將達到 567.5 億美元，到 2026 年將成長至 615 億美元，到 2032 年將達到 1039.6 億美元，複合年成長率為 9.03%。

主要市場統計數據
基準年 2025 567.5億美元
預計年份：2026年 615億美元
預測年份 2032 1039.6億美元
複合年成長率 (%) 9.03%

非處方藥市場正經歷前所未有的變革，其驅動力包括消費者行為的根本轉變、監管機構對自我護理的支持以及技術的快速發展。實體零售曾經佔據主導地位，而如今，該市場已涵蓋了廣泛的數位化和混合管道，以滿足不同人群的需求，包括注重健康的千禧世代、逐漸老齡化的嬰兒潮世代以及發展中地區新興的中產階級。近年來，人們對預防性健康解決方案的需求激增，推動了新配方和包裝設計的創新，這些創新優先考慮便利性和依從性。

在這種瞬息萬變的環境中，監管機構的角色也在發生變化，他們需要應對快速變化的用途變更計劃和統一的標籤指南，這些計劃和指南在優先考慮安全性的同時，降低了市場准入門檻。因此，產業相關人員正在重新思考其產品開發、供應鏈韌性和全通路行銷策略。直接面對消費者的廣告和網紅合作進一步提高了產品知名度，使小眾品牌能夠挑戰行業主要企業。

本執行摘要系統整體情況了波動性與機會並存的非處方藥（OTC）市場。它說明了關鍵市場促進因素、重要的監管動態以及塑造產業未來發展方向的策略挑戰。讀者將清晰了解變革性趨勢、市場區隔洞察、區域發展、競爭定位以及對永續成長和建立競爭優勢至關重要的切實可行的建議。

在數位醫療整合、監管變革和消費者偏好變化的推動下，非處方藥市場正在發生變革性變化。

在數位健康平台整合、監管政策日益嚴格以及消費者期望不斷變化等因素的推動下，非處方藥市場正經歷著根本性的變革。遠端醫療應用和人工智慧症狀自查工具正在簡化購買流程，而行動醫療錢包和訂閱模式則將個人化護理方案直接送到患者家中。此外，虛擬藥房的蓬勃發展正在革新傳統的零售模式，透過數據驅動的推薦，實現更快的產品交付和更深入的消費者互動。

檢驗2025 年美國關稅對非處方藥供應鏈、定價結構和州際貿易趨勢的累積影響。

美國於2025年實施的新關稅對藥品供應鏈、定價策略和貿易流量產生了累積影響。這些關稅針對關鍵的醫藥原料和包裝組件，進一步加劇了依賴從成熟化工基地進口活性藥物成分（API）的製造商的成本壓力。因此，許多公司面臨利潤空間受限的困境，並被迫重新評估籌資策略。

透過對非處方藥類型、劑型、分銷管道、年齡層和最終用戶概況進行詳細的細分分析，開發成長機會。

對市場區隔的深入理解揭示了各個治療領域、劑型、分銷管道、人口統計細分和終端用戶畫像等方面的精準市場機會。就藥物類型而言，感冒、咳嗽和過敏類藥物可細分為抗組織胺、止咳藥和減充血劑，反映了季節性疾病和慢性疾病的不同需求模式。皮膚科和護膚領域涵蓋痤瘡治療藥物、抗真菌乳膏和皮膚保護劑，滿足美容和臨床應用需求。消化器官系統健康產品種類繁多，從制酸劑到止瀉和瀉藥，涵蓋從緩解暫時性症狀到長期胃腸道管理的各種需求。眼耳護理產品滿足感官舒適和衛生需求，而鎮痛藥則涵蓋範圍廣泛，包括非類固醇消炎劑(NSAIDs) 和局部鎮痛藥。最後，維生素和膳食補充劑在注重預防性健康維護的人中保持著強勁的需求。

一份全面的區域展望報告，重點介紹了美洲、歐洲、中東、非洲和亞太地區非處方藥 (OTC) 行業的市場動態。

非處方藥（OTC）市場的區域趨勢在美洲、歐洲、中東、非洲和亞太地區差異顯著，每個地區都面臨著各自獨特的挑戰和成長機會。美洲市場已趨於成熟，人均非處方藥消費量較高，超級市場自有品牌藥的擴張以及面向消費者的數位平台創新仍在持續。北美地區監管協調的努力正在促進跨境產品上市，而消費者則更加關注循證處方和以生活方式為導向的自我護理習慣。

對推動非處方藥市場趨勢的主要製藥和消費保健公司進行策略性競爭考察。

非處方藥市場的競爭格局由全球製藥巨頭、專業消費保健品製造商和靈活的區域企業共同塑造。領先的跨國公司憑藉多元化的產品系列、持續的研發投入以及覆蓋傳統和數位零售通路的廣泛分銷網路，保持著市場領先地位。它們的規模優勢使其能夠高效採購並快速進行全球部署，從而為小規模、新參與企業設置了巨大的准入門檻。

為行業領導者提供實用且具前瞻性的建議，以掌握非處方藥市場的新趨勢。

產業領導者若想在不斷發展的非處方藥市場中獲利，需要採取多管齊下的策略，將數位創新、監管適應性和密切的消費者互動結合在一起。首先，將先進的分析功能整合到消費者互動平台中，可實現個人化推薦、精準促銷和完善的產品開發藍圖。此外，改進的數據處理能力支援動態定價模型，該模型能夠根據成本波動和競爭壓力即時調整價格。

採用綜合研究途徑，結合一手訪談和二手資料分析，為非處方藥（OTC）產業提供公正的見解。

本研究採用綜合調查方法，整合了第一手訪談、二手資料分析和嚴格的專家檢驗，以確保獲得可靠且客觀的見解。第一手研究包括對製藥和消費保健公司高階主管、供應鏈專家、監管顧問和數位醫療創新者進行結構化訪談。這些對話提供了關於策略挑戰、投資重點和新興市場機會的第一手觀點。

總結策略展望，整合關鍵市場促進因素和新興趨勢，以塑造非處方藥產業的未來成長軌跡。

總而言之，非處方藥市場正處於一個關鍵的十字路口，其發展受到數位轉型、監管環境演變和消費者期望變化的影響。關稅壓力、精細化的市場區隔和區域趨勢的相互作用凸顯了供應鏈韌性和策略敏捷性的重要性。競爭優勢取決於能否有效利用數據驅動的洞察，與監管機構建立夥伴關係，並在不同的治療領域和人群中提供精準的產品和服務。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按藥物類型分類的非處方藥市場

  • 感冒、咳嗽和過敏藥物
    • 抗組織胺藥
    • 止咳藥
    • 減充血劑
  • 皮膚病學和護膚
    • 痤瘡治療藥物
    • 抗真菌乳膏
    • 皮膚保護劑
  • 消化器官系統
    • 制酸劑
    • 止瀉
    • 瀉藥
  • 眼耳護理
  • 止痛藥
  • 維生素和補充劑

第9章：非處方藥市場：依產品形式分類

  • 膠囊
  • 液體/糖漿
  • 粉末
  • 噴
  • 栓劑
  • 片劑/藥丸
  • 外用乳霜/軟膏/凝膠

第10章 非處方藥市場：依分銷管道分類

  • 離線
    • 藥局/藥局
    • 超級市場和大賣場
  • 線上

第11章 非處方藥市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第12章 非處方藥市場：依最終使用者分類

  • 醫療保健專業人員
  • 一般消費者
  • 機構用戶

第13章 非處方藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 非處方藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 非處方藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國非處方藥市場

第17章：中國非處方藥市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Inc.
  • Genomma group
  • GSK plc
  • Hisamitsu Pharmaceutical Co., Inc.
  • Johnson & Johnson Services, Inc.
  • LNK International, Inc.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Pierre Fabre SA
  • PL Developments LLC
  • Procter & Gamble Manufacturing Company
  • Reckitt Benckiser LLC
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Taisho Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd
  • The Mentholatum Company, Inc.
  • Tris Pharma, Inc.
  • Viatris Inc.
  • Worwag Pharma GmbH & Co. KG
  • Zentiva Group, as
Product Code: MRR-436297358D26

The Over The Counter Drugs Market was valued at USD 56.75 billion in 2025 and is projected to grow to USD 61.50 billion in 2026, with a CAGR of 9.03%, reaching USD 103.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 56.75 billion
Estimated Year [2026] USD 61.50 billion
Forecast Year [2032] USD 103.96 billion
CAGR (%) 9.03%

The over-the-counter drug sector has entered a period of unprecedented transformation, driven by fundamental shifts in consumer behavior, regulatory support for self-care, and rapid technological advances. Once dominated by brick-and-mortar distribution, the landscape now spans a spectrum of digital and hybrid channels that cater to a demographic blend of health-conscious millennials, aging baby boomers, and emerging middle classes in developing regions. Recent years have seen a surge in demand for preventive wellness solutions, prompting manufacturers to innovate with novel formulations and packaging designs that emphasize convenience and adherence.

Amid this dynamic environment, the role of regulatory agencies has evolved to accommodate expedited switch programs and harmonized labeling guidelines that prioritize safety while reducing barriers for market entry. Consequently, industry participants are recalibrating their approaches to product development, supply chain resilience, and omnichannel marketing. The influence of direct-to-consumer advertising and influencer partnerships has further accelerated product visibility, enabling niche brands to challenge established incumbents.

This executive summary provides a cohesive introduction to the volatile yet opportunity-rich over-the-counter drug landscape. It outlines the key market drivers, pivotal regulatory developments, and strategic imperatives shaping the industry's next chapter. Readers will gain clarity on transformative trends, segmentation insights, regional dynamics, competitive positioning, and actionable recommendations essential for sustained growth and competitive differentiation.

Transformative Shifts Reshaping the Over-the-Counter Drug Landscape Driven by Digital Health Integration, Regulatory Changes, and Changing Consumer Preferences

The over-the-counter drug market is undergoing profound transformative shifts, propelled by the integration of digital health platforms, intensified regulatory changes, and evolving consumer expectations. Telemedicine applications and AI-driven symptom checkers now streamline the purchase journey, while mobile health wallets and subscription models offer personalized care regimens directly to patients' homes. Moreover, the proliferation of virtual pharmacies has disrupted traditional retail models, enabling faster fulfillment and deeper consumer engagement through data-driven recommendations.

Parallel to these digital innovations, regulatory agencies across key markets have implemented reforms to expedite switch-to-OTC processes and standardize safety protocols. These changes have reduced the time and cost associated with bringing new therapies to over-the-counter status, encouraging firms to allocate greater resources to clinical research and real-world evidence generation. In turn, the market has seen an influx of once-prescription treatments, expanding therapeutic options in dermatology, gastrointestinal health, and respiratory care.

Concurrently, consumer preferences are shifting toward clean-label formulations, sustainable packaging, and transparent sourcing practices. Health-conscious shoppers are increasingly scrutinizing ingredient lists and favoring brands that demonstrate environmental stewardship. This confluence of digital advancement, regulatory alignment, and heightened consumer awareness is redefining competitive advantage in the OTC drug arena, compelling stakeholders to adopt agile strategies that balance innovation with compliance and brand authenticity.

Examining the Cumulative Impact of United States Tariffs in 2025 on Over-the-Counter Drug Supply Chains, Pricing Structures, and Interstate Trade Dynamics

The implementation of new United States tariff measures in 2025 has exerted a cumulative impact on over-the-counter drug supply chains, pricing strategies, and trade flows. These levies, targeting key pharmaceutical ingredients and packaging components, have introduced additional cost pressures on manufacturers reliant on imported active pharmaceutical ingredients (APIs) from established chemical hubs. As a result, many companies have experienced margin compression and have been compelled to reassess procurement strategies.

In response, stakeholders have accelerated efforts to develop localized API production capabilities and form strategic alliances with domestic suppliers. Inventory management practices have also adapted, with firms increasing safety stock levels to buffer against tariff-induced disruptions. Additionally, dynamic pricing models have emerged, enabling swift adjustment of consumer-facing prices to reflect input cost fluctuations while preserving affordability.

Beyond supply chain realignment, the tariff landscape has stimulated a broader reevaluation of global sourcing footprints. Companies are diversifying alternative manufacturing locations across Asia-Pacific and Latin America to mitigate exposure. These strategic shifts are enhancing resilience but require careful navigation of regulatory approvals and quality standards. Ultimately, the tariff environment of 2025 has catalyzed a wave of strategic realignments that are redefining competitive positioning and supply chain configurations within the over-the-counter drug market.

Unlocking Growth Opportunities Through In-Depth Segmentation Analysis of Over-the-Counter Drug Types, Forms, Channels, Age Groups, and End-User Profiles

A nuanced understanding of market segmentation reveals targeted opportunities across therapeutic categories, dosage forms, distribution channels, demographic cohorts, and end-user profiles. In the realm of drug types, the cold, cough, and allergy category subdivides into antihistamines, cough suppressants, and decongestants, reflecting differentiated demand patterns across seasonal and chronic conditions. Dermatology and skin care encompasses acne treatments, antifungal creams, and skin protectants, catering to both cosmetic and clinical use cases. Digestive health products range from antacids to anti-diarrheal remedies and laxatives, responding to episodic and long-term gastrointestinal management. Eye and ear care solutions address sensory comfort and hygiene needs, while pain relief medications span nonsteroidal analgesics and topical analgesic formulations. Finally, vitamins and supplements continue to enjoy robust demand from preventive wellness advocates.

Product form segmentation further illuminates consumer preferences, encompassing capsules, liquids and syrups, powders, sprays, suppositories, tablets and pills, as well as topical creams, ointments, and gels. Each format aligns with specific administration considerations, such as pediatric dosing comfort, geriatric swallowing ease, or localized delivery.

Distribution channels exhibit a bifurcation between offline and online pathways, with offline channels structured around pharmacies, drug stores, supermarkets, and hypermarkets that emphasize immediate accessibility. Online channels leverage e-commerce platforms and direct-to-consumer portals, facilitating subscription offerings and telehealth integration.

Demographic segmentation underscores divergent needs among adult, geriatric, and pediatric populations, each demanding tailored formulations, dosage strengths, and packaging ergonomics. Similarly, end-user segmentation distinguishes healthcare professionals prescribing or recommending OTC therapies, individual consumers driving retail purchases, and institutional users such as hospitals, long-term care facilities, and corporate wellness programs procuring products in bulk. This layered segmentation framework enables precision targeting of product portfolios, marketing strategies, and supply chain allocations.

Comprehensive Regional Perspective Highlighting Market Dynamics Across Americas, Europe Middle East & Africa, and Asia-Pacific Over-the-Counter Drug Sectors

Regional dynamics in the over-the-counter drug market vary substantially across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting unique challenges and growth catalysts. In the Americas, a mature market characterized by high per-capita OTC consumption continues to innovate through private-label expansions in supermarkets and direct-to-consumer digital platforms. Regulatory harmonization efforts in North America facilitate cross-border product launches, while consumer expectations center on evidence-based formulations and lifestyle-oriented self-care routines.

The Europe Middle East & Africa region encompasses a broad array of regulatory environments, distribution infrastructures, and economic conditions. Western Europe's advanced regulatory frameworks and robust pharmacy networks support rapid adoption of novel OTC switches, whereas emerging economies in Eastern Europe and the Middle East prioritize affordability and access through generic alternatives and multinational partnerships. In Africa, the rise of mobile health initiatives and localized manufacturing hubs is gradually improving product availability and driving interest in mobile pharmacies and e-health platforms.

In contrast, Asia-Pacific stands out as the fastest-growing regional market, fuelled by rising disposable incomes, urbanization, and expanding healthcare access. Countries in East and Southeast Asia are witnessing surges in online pharmacy usage and cross-border purchases, while South Asia's dense population base accelerates demand for cost-effective self-care solutions. Collaborative ventures between domestic innovators and global players are enhancing technology transfer, creating a dynamic environment for product innovation and regulatory advancement.

Strategic Competitive Insights into Leading Pharmaceutical and Consumer Healthcare Companies Shaping the Over-the-Counter Drug Market Landscape

The competitive landscape of the over-the-counter drug market is shaped by global pharmaceutical giants, specialized consumer healthcare manufacturers, and agile regional players. Prominent multinational corporations maintain leadership through diversified portfolios, continuous R&D investment, and expansive distribution networks that span both traditional retail and digital channels. Their scale enables procurement efficiencies and rapid global launch capabilities, creating significant barriers for smaller entrants.

Meanwhile, niche innovators and private-label purveyors have carved out differentiation by focusing on natural and botanical formulations, premium wellness positioning, and direct engagement with consumer communities. These companies leverage e-commerce analytics and personalized marketing campaigns to gain traction in specific segments such as dermatology, digestive health, and nutritional supplements.

Regional champions in emerging markets are also gaining prominence by tailoring product offerings to local preferences and regulatory frameworks. Some have optimized cost structures through regional manufacturing hubs and strategic alliances with contract development and manufacturing organizations. Collectively, these competitive approaches underscore the importance of agility, brand authenticity, and supply chain resilience in securing sustainable market share.

Practical and Forward-Looking Recommendations Empowering Industry Leaders to Capitalize on Emerging Trends in Over-the-Counter Drug Markets

Industry leaders seeking to capitalize on the evolving over-the-counter drug market must adopt a multipronged strategic agenda that blends digital innovation, regulatory agility, and consumer intimacy. Firstly, integrating advanced analytics into consumer engagement platforms will enable personalized recommendations, targeted promotions, and refined product development roadmaps. Enhanced data capabilities will also support dynamic pricing models that adjust in real time to input cost fluctuations and competitive pressures.

Secondly, firms should pursue localized manufacturing partnerships and invest in onshore API production to mitigate tariff exposure and reduce supply chain complexity. Developing contingency plans with alternate suppliers and maintaining strategic stock reserves will further enhance resilience against geopolitical disruptions.

Thirdly, expanding into adjacent wellness categories-such as nutraceuticals, functional foods, and digital therapeutics-can unlock cross-selling synergies and attract health-oriented consumers. Collaborations with telehealth providers and integration with health monitoring devices will position organizations at the intersection of prevention and treatment.

Finally, embedding sustainability principles across product life cycles, from ingredient sourcing to packaging design, will resonate with environmentally conscious consumers and align with emerging regulatory mandates. By prioritizing these actionable recommendations, industry leaders can strengthen market positioning and drive long-term, profitable growth.

Comprehensive Research Approach Leveraging Primary Interviews and Secondary Data Analysis to Deliver Unbiased Insights into Over-the-Counter Drug Sector

This research draws upon a comprehensive methodology that synthesizes primary interviews, secondary data analysis, and rigorous expert validation to ensure robust and unbiased insights. Primary research involved structured interviews with senior executives from pharmaceutical and consumer healthcare companies, supply chain specialists, regulatory consultants, and digital health innovators. These conversations provided firsthand perspectives on strategic challenges, investment priorities, and emerging market opportunities.

Secondary research encompassed a systematic review of regulatory filings, industry periodicals, corporate annual reports, and technical white papers. Publicly available data from government agencies and trade associations was triangulated with proprietary sources to enhance data accuracy and contextual depth. Quantitative analyses employed advanced statistical techniques to identify consumption patterns, channel shifts, and demographic influences across multiple geographies.

Finally, an expert validation process convened cross-functional industry advisors to critique preliminary findings, refine segmentation frameworks, and vet strategic recommendations. This iterative approach ensured that conclusions reflect the latest market developments and operational realities, offering decision-makers a credible foundation for strategic planning.

Concluding Strategic Perspectives Synthesizing Key Market Drivers and Emerging Trends Shaping Future Growth Trajectories in Over-the-Counter Drug Industry

In summary, the over-the-counter drug market stands at a pivotal juncture defined by digital disruption, regulatory evolution, and shifting consumer expectations. The interplay of tariff pressures, segmentation nuances, and regional dynamics underscores the importance of supply chain resilience and strategic agility. Competitive success will hinge on the ability to harness data-driven insights, cultivate regulatory partnerships, and deliver targeted offerings across therapeutic categories and demographic groups.

As market participants navigate this complex environment, those who embrace innovation in manufacturing, distribution, and marketing will secure the greatest advantage. Proactive investments in localized production, sustainable practices, and consumer personalization will strengthen brand loyalty and foster long-term growth. By internalizing the strategic recommendations outlined herein, organizations can chart a clear path forward and translate market intelligence into differentiated value propositions.

Ultimately, the insights presented in this summary provide a strategic roadmap for executives, investors, and stakeholders aiming to capitalize on the accelerating momentum within the over-the-counter drug sector. The confluence of emerging technologies, consumer empowerment, and regulatory reforms offers a fertile landscape for innovation and competitive advancement.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Over The Counter Drugs Market, by Drug Type

  • 8.1. Cold, Cough, & Allergy Medications
    • 8.1.1. Antihistamines
    • 8.1.2. Cough Suppressants
    • 8.1.3. Decongestants
  • 8.2. Dermatology & Skin Care
    • 8.2.1. Acne Treatments
    • 8.2.2. Antifungal Creams
    • 8.2.3. Skin Protectants
  • 8.3. Digestive Health
    • 8.3.1. Antacids
    • 8.3.2. Anti-diarrheal
    • 8.3.3. Laxatives
  • 8.4. Eye & Ear Care
  • 8.5. Pain Relief Medications
  • 8.6. Vitamins & Supplements

9. Over The Counter Drugs Market, by Product Form

  • 9.1. Capsules
  • 9.2. Liquids/Syrups
  • 9.3. Powders
  • 9.4. Sprays
  • 9.5. Suppositories
  • 9.6. Tablets/Pills
  • 9.7. Topical Creams/Ointments/Gels

10. Over The Counter Drugs Market, by Distribution Channel

  • 10.1. Offline
    • 10.1.1. Pharmacies & Drug Stores
    • 10.1.2. Supermarkets & Hypermarkets
  • 10.2. Online

11. Over The Counter Drugs Market, by Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Over The Counter Drugs Market, by End-user

  • 12.1. Healthcare Professionals
  • 12.2. Individual Consumers
  • 12.3. Institutional Users

13. Over The Counter Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Over The Counter Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Over The Counter Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Over The Counter Drugs Market

17. China Over The Counter Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amneal Pharmaceuticals LLC
  • 18.6. Aurobindo Pharma Limited
  • 18.7. Bayer AG
  • 18.8. Cipla Limited
  • 18.9. Dr. Reddy's Laboratories Inc.
  • 18.10. Genomma group
  • 18.11. GSK plc
  • 18.12. Hisamitsu Pharmaceutical Co., Inc.
  • 18.13. Johnson & Johnson Services, Inc.
  • 18.14. LNK International, Inc.
  • 18.15. Novartis AG
  • 18.16. Perrigo Company plc
  • 18.17. Pfizer Inc.
  • 18.18. Pierre Fabre S.A
  • 18.19. PL Developments LLC
  • 18.20. Procter & Gamble Manufacturing Company
  • 18.21. Reckitt Benckiser LLC
  • 18.22. Sanofi S.A.
  • 18.23. Sun Pharmaceutical Industries Limited
  • 18.24. Taisho Pharmaceutical Co., Ltd.
  • 18.25. Teva Pharmaceutical Industries Ltd
  • 18.26. The Mentholatum Company, Inc.
  • 18.27. Tris Pharma, Inc.
  • 18.28. Viatris Inc.
  • 18.29. Worwag Pharma GmbH & Co. KG
  • 18.30. Zentiva Group, a.s.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH SUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH SUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DECONGESTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DECONGESTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DECONGESTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ACNE TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ACNE TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ACNE TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIFUNGAL CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIFUNGAL CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIFUNGAL CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SKIN PROTECTANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SKIN PROTECTANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SKIN PROTECTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTI-DIARRHEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTI-DIARRHEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTI-DIARRHEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY EYE & EAR CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY EYE & EAR CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY EYE & EAR CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PAIN RELIEF MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PAIN RELIEF MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PAIN RELIEF MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LIQUIDS/SYRUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LIQUIDS/SYRUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LIQUIDS/SYRUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPPOSITORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPPOSITORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TABLETS/PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TABLETS/PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TABLETS/PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS/GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS/GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS/GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PHARMACIES & DRUG STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PHARMACIES & DRUG STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PHARMACIES & DRUG STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPERMARKETS & HYPERMARKETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPERMARKETS & HYPERMARKETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPERMARKETS & HYPERMARKETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INSTITUTIONAL USERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INSTITUTIONAL USERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INSTITUTIONAL USERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 204. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 205. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GCC OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 229. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 233. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 234. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 235. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 237. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 238. G7 OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 239. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 244. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 245. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 247. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 248. NATO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA OVER THE COUNTER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)